What is HC Wainwright’s Forecast for AUTL Q3 Earnings?

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL – Free Report) – Research analysts at HC Wainwright issued their Q3 2026 earnings per share estimates for Autolus Therapeutics in a research report issued on Monday, November 2nd. HC Wainwright analyst D. Tsao anticipates that the company will post earnings of ($0.20) per share for the quarter. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($0.76) per share. HC Wainwright also issued estimates for Autolus Therapeutics’ Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($0.81) EPS, FY2027 earnings at ($0.74) EPS, FY2028 earnings at ($0.86) EPS, FY2029 earnings at ($0.73) EPS and FY2030 earnings at ($0.26) EPS.

Several other equities analysts also recently issued reports on AUTL. Wall Street Zen raised shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, August 16th. Weiss Ratings cut shares of Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $10.00.

View Our Latest Report on AUTL

Autolus Therapeutics Trading Down 8.7%

Shares of NASDAQ AUTL opened at $1.26 on Wednesday. The company has a debt-to-equity ratio of 1.04, a quick ratio of 4.40 and a current ratio of 4.89. Autolus Therapeutics has a 52-week low of $1.18 and a 52-week high of $2.58. The firm has a 50 day moving average price of $1.83 and a two-hundred day moving average price of $1.66. The stock has a market cap of $335.36 million, a P/E ratio of -1.19 and a beta of 2.32.

Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.06. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. The business had revenue of $45.69 million during the quarter, compared to analyst estimates of $38.56 million.

Hedge Funds Weigh In On Autolus Therapeutics

A number of hedge funds have recently made changes to their positions in AUTL. Privium Fund Management B.V. increased its position in Autolus Therapeutics by 29.2% during the 3rd quarter. Privium Fund Management B.V. now owns 469,490 shares of the company’s stock valued at $911,000 after purchasing an additional 106,060 shares during the period. Vise Technologies Inc. acquired a new position in shares of Autolus Therapeutics in the 3rd quarter worth approximately $35,000. QRG Capital Management Inc. lifted its position in shares of Autolus Therapeutics by 67.7% in the 2nd quarter. QRG Capital Management Inc. now owns 18,325 shares of the company’s stock worth $29,000 after purchasing an additional 7,400 shares during the period. Alphabet Inc. bought a new stake in shares of Autolus Therapeutics in the 2nd quarter valued at $1,117,000. Finally, Syncona Portfolio Ltd bought a new stake in shares of Autolus Therapeutics in the 2nd quarter valued at $26,625,152. 72.83% of the stock is currently owned by institutional investors.

Key Stories Impacting Autolus Therapeutics

Here are the key news stories impacting Autolus Therapeutics this week:

  • Positive Sentiment: Autolus said abstracts for clinical data updates have been published ahead of the American Society of Hematology (ASH) Annual Meeting, scheduled for December 12–15. The presentations could provide a catalyst if the data strengthen confidence in the company’s cell-therapy programs, though the announcement itself did not disclose the findings. Autolus ASH data update announcement
  • Positive Sentiment: HC Wainwright initiated coverage with a Buy rating, offering a supportive analyst signal. HC Wainwright begins coverage on Autolus Therapeutics
  • Negative Sentiment: HC Wainwright’s forecasts anticipate continued losses, including a loss of $0.81 per share for 2026 and $0.86 for 2028. Its Q3 and Q4 2026 estimates are both losses of $0.20 per share; these projections may weigh on sentiment despite the Buy rating.

About Autolus Therapeutics

(Get Free Report)

Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing programmed T-cell therapies for cancer. The company’s approach is designed to engineer T cells to recognize and eliminate malignant cells while incorporating features intended to improve activity, persistence and safety.

Its lead product, obecabtagene autoleucel, is an autologous CAR T-cell therapy marketed in the United States under the brand name Aucatzyl. It is used to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Recommended Stories

Earnings History and Estimates for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.